Clinical trials: Female Osteoporosis
Osteoporosis, Postmenopausal
Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
To confirm the superiority of 5 mg daily risedronate as compared to placebo in maintaining or increasing bone mass in lumbar spine in osteopenic postmenopausal women To confirm the efficacy of 5 mg daily risedronate in osteopenic…
- Trial name
- NCT00353080
- Testing
- risedronate (HMR4003)
- Where
- 5 sites in Finland, Netherlands and 3 more
- Volunteers
- 171 people
- Sponsor
- Sanofi
Osteoporosis
Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
The objective is to show superior efficacy of PTH (1-84) over risedronate in treating osteoporotic women for 12 months after having previously been treated with PTH (1-84) for 12 months followed by 12 months treatment with…
- Trial name
- PEAK (NCT00365456)
- Testing
- Parathyroid Hormone (PTH), Risedronate
- Where
- Denmark
- Volunteers
- 407 people
- Sponsor
- Takeda
Osteoporosis
CONFIRM - Study of AGN1 LOEP in Patients With Osteoporosis
The study will evaluate the immediate procedure and post-procedure profile of the AGN1 Femoral LOEP™ Kit. All subjects will receive the treatment and be evaluated for any adverse or serious adverse events that could occur during…
- Trial name
- NCT02916953
- Testing
- AGN1 Femoral Local Osteo-Enhancement Procedure
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 60 people
- Sponsor
- AgNovos Healthcare, LLC
Osteoporosis, Post-Menopausal
Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
To see if using teriparatide for 12 months will increase Bone Mineral Density at the lumbar spine in postmenopausal women with osteoporosis
- Trial name
- NCT00532207
- Testing
- teriparatide
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
The purpose of this study is to determine whether TSE-424 (bazedoxifene acetate), an investigational drug, is safe and effective in the prevention of osteoporosis in postmenopausal women.
- Trial name
- NCT00481169
- Testing
- Bazedoxifene Acetate (TSE-424)
- Volunteers
- 1,742 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopausal Osteoporosis
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.
- Trial name
- VERO (NCT01709110)
- Testing
- Teriparatide, Risedronate, Calcium
- Where
- 103 sites in United States, Argentina and 13 more
- Volunteers
- 1,366 people
- Sponsor
- Eli Lilly and Company
Osteoporosis, Postmenopausal
Denosumab China Phase III Study
This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.
- Trial name
- NCT02014467
- Testing
- Denosumab, Elemental Calcium, Vitamin D
- Where
- 8 sites in China
- Volunteers
- 486 people
- Sponsor
- GlaxoSmithKline
Osteoporosis
Calcium Supplementation in Postmenopausal Women
This study is evaluating the effects of calcium supplementation on the efficacy and safety of recombinant parathyroid hormone (ALX1-11) in postmenopausal women with osteoporosis.
- Trial name
- CAP (NCT00172172)
- Testing
- PTH/Calcium
- Where
- 27 sites in United States, Argentina and 1 more
- Volunteers
- 374 people
- Sponsor
- Shire
Osteoporosis, Postmenopausal Osteoporosis
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)
This study will evaluate the therapeutic effects and safety of odanacatib on bone mineral density in osteoporotic postmenopausal women who were previously treated with alendronate.
- Trial name
- NCT01552122
- Testing
- Odanacatib, Alendronate, Cholecalciferol (Vitamin D3)
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
- Trial name
- NCT06504966
- Testing
- MAB-22, Prolia®
- Sponsor
- Xentria, Inc.
Osteoporosis
Clinical Trial of Teriparatide in Japan
The purpose of this study is to assess the Efficacy and Safety of Teriparatide in Japanese Postmenopausal Women with Osteoporosis.
- Trial name
- NCT00191867
- Testing
- Teriparatide
- Where
- 6 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis
The purpose of this study is to evaluate the effects of teriparatide on skeleton images in postmenopausal women with osteoporosis. Teriparatide is a bone formation agent that stimulates the production of new bone in the skeleton.
- Trial name
- NCT00259298
- Testing
- teriparatide
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)
The purpose of this study is to assess to what extent sequential treatment with odanacatib results in incremental gains in bone mineral density (BMD) over time in female participants who have received at least 3 years of…
- Trial name
- NCT01803607
- Testing
- odanacatib
- Volunteers
- 135 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
Clinical Study of AK159 in Healthy Postmenopausal Women
The objective of this study is to investigate the pharmacokinetics, safety, and tolerability of AK159 administered to healthy postmenopausal women.
- Trial name
- NCT01551602
- Testing
- AK159, MN-10-T
- Where
- 3 sites in Japan
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Asahi Kasei Therapeutics Corporation
Osteoporosis, Postmenopausal
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)
The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.
- Trial name
- NCT00389740
- Testing
- MK0217, /Duration of Treatment : 12 Months, Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months
- Volunteers
- 400 people
- Sponsor
- Organon and Co
Low Bone Mineral Density
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density
- Trial name
- NCT00325468
- Testing
- AMG 162
- Volunteers
- 200 people
- Sponsor
- Amgen
Osteoporosis
TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density
This is a placebo-controlled, single-ascending dose, multicenter Phase I clinical study to evaluate the safety, tolerability, PK and PD characteristics of a single intravenous infusion of TST002 in subjects with reduced bone…
- Trial name
- NCT05391776
- Testing
- TST002 Injection
- Where
- 5 sites in China
- Volunteers
- 32 people
- Sponsor
- HJB (Hangzhou) Co., Ltd.
Postmenopausal
A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture
This is a randomized, double-blind, international multicentre, parallel-controlled phase III clinical study. The study plans to enroll 478 postmenopausal women with osteoporosis at high risk of fracture, whom will be randomized…
- Trial name
- NCT05352516
- Testing
- HLX14, Prolia®
- Where
- 38 sites in China
- Volunteers
- 514 people
- Sponsor
- Shanghai Henlius Biotech
Osteoporosis, Postmenopausal
Satisfaction and Compliance of Risedronate in PMO
Compare subject satisfaction of once a week dosing of 35 mg Risedronate to once daily dosing of 5 mg Risedronate in postmenopausal osteoporotic women.
- Trial name
- NCT00549965
- Testing
- Risedronate Sodium
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Sanofi
Postmenopausal Women With Osteoporosis
A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.
This was a randomized, double-blind, parallel, multicenter, multinational study to compare the efficacy, pharmacokinetics, pharmacodynamics, safety and immunogenicity of MB09 versus Prolia® in postmenopausal women with…
- Trial name
- NCT05338086
- Testing
- MB09 (denosumab biosimilar), EU-Prolia, Elemental Calcium
- Where
- 64 sites in Bulgaria, Estonia and 6 more
- Volunteers
- 558 people
- Sponsor
- mAbxience Research S.L.